Drugs

$Paolo Tarantino: Trastuzumab deruxtecan is now FDA approved for ANY treatment-refractory HER2+ solid tumor$

Photo from Paolo Tarantino/LinkedIn

Apr 8, 2024, 03:54

Paolo Tarantino: Trastuzumab deruxtecan is now FDA approved for ANY treatment-refractory HER2+ solid tumor

Paolo Tarantino, Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“Trastuzumab deruxtecan (T-DXd) is now FDA approved for the treatment of patients with ANY treatment-refractory HER2+ (IHC 3+) solid tumor, making it the first agnostic ADC. Unlikely to be the last. First priority: ensuring that HER2 testing is expanded across cancer types. Exciting times!”

Read further.
Source: Paolo Tarantino/LinkedIn

agnostic ADC breast oncology cancer Dana-Farber Cancer Institute FDA FDA approved HER2 OncoDaily Oncology Paolo Tarantino Trastuzumab Deruxtecan (T-DXd)

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer